Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy by Ottenheijm, Ca et al.
BRAIN
A JOURNAL OF NEUROLOGY
Deleting exon 55 from the nebulin gene induces
severe muscle weakness in a mouse model
for nemaline myopathy
Coen A. C. Ottenheijm,1,2 Danielle Buck,2 Josine M. de Winter,1 Claudia Ferrara,3
Nicoletta Piroddi,3 Chiara Tesi,3 Jeffrey R. Jasper,4 Fady I. Malik,4 Hui Meng,5 Ger J. M. Stienen,1,6
Alan H. Beggs,7 Siegfried Labeit,8 Corrado Poggesi,3 Michael W. Lawlor5 and Henk Granzier2
1 Department of Physiology, VU University Medical Centre, Amsterdam, The Netherlands
2 Department of Physiology, University of Arizona, Tucson, AZ, USA
3 Department of Physiology, University of Florence, Florence, Italy
4 Research and Early Development, Cytokinetics, Inc., South San Francisco, CA, USA
5 Division of Paediatric Pathology, Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
6 Department of Physics and Astronomy, VU University, Amsterdam, The Netherlands
7 Division of Genetics and Program in Genomics, The Manton Centre for Orphan Disease Research, Boston Children’s Hospital, Harvard Medical
School, Boston, MA, USA
8 Department for Integrative Pathophysiology, Medical Faculty Mannheim, University of Heidelberg, Germany
Correspondence to: Henk Granzier,
Department of Physiology,
University of Arizona, P.O. Box 245217,
Tucson, AZ 85724, USA
E-mail: granzier@email.arizona.edu
Nebulin—a giant sarcomeric protein—plays a pivotal role in skeletal muscle contractility by specifying thin filament length and
function. Although mutations in the gene encoding nebulin (NEB) are a frequent cause of nemaline myopathy, the most common
non-dystrophic congenital myopathy, the mechanisms by which mutations in NEB cause muscle weakness remain largely un-
known. To better understand these mechanisms, we have generated a mouse model in which Neb exon 55 is deleted (NebExon55)
to replicate a founder mutation seen frequently in patients with nemaline myopathy with Ashkenazi Jewish heritage. NebExon55
mice are born close to Mendelian ratios, but show growth retardation after birth. Electron microscopy studies show nemaline
bodies—a hallmark feature of nemaline myopathy—in muscle fibres from NebExon55 mice. Western blotting studies with nebulin-
specific antibodies reveal reduced nebulin levels in muscle from NebExon55 mice, and immunofluorescence confocal microscopy
studies with tropomodulin antibodies and phalloidin reveal that thin filament length is significantly reduced. In line with reduced
thin filament length, the maximal force generating capacity of permeabilized muscle fibres and single myofibrils is reduced in
NebExon55 mice with a more pronounced reduction at longer sarcomere lengths. Finally, in NebExon55 mice the regulation of
contraction is impaired, as evidenced by marked changes in crossbridge cycling kinetics and by a reduction of the calcium
sensitivity of force generation. A novel drug that facilitates calcium binding to the thin filament significantly augmented the
calcium sensitivity of submaximal force to levels that exceed those observed in untreated control muscle. In conclusion, we have
characterized the first nebulin-based nemaline myopathy model, which recapitulates important features of the phenotype observed
in patients harbouring this particular mutation, and which has severe muscle weakness caused by thin filament dysfunction.
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Introduction
Nemaline myopathy is the most common non-dystrophic congeni-
tal myopathy (Sanoudou and Beggs, 2001), with hallmark features
that include muscle weakness and the presence of nemaline bodies
in skeletal muscle fibres (North et al., 1997). To date, seven genes
have been implicated in nemaline myopathy. Strikingly, six of
these genes code for proteins of the skeletal muscle thin filament:
alpha tropomyosin 3 and beta tropomyosin (TPM3 and TPM2),
nebulin (NEB), actin alpha 1 (ACTA1), troponin T type 1 (TNNT1),
and cofilin 2 (CFL2). The seventh implicated gene, KBTBD13,
encodes a ubiquitin ligase whose function in skeletal muscle is
currently unknown (Sambuughin et al., 2010, 2012). With muta-
tions in NEB likely accounting for 450% of nemaline myopathy
cases (Pelin et al., 1999), NEB is the most frequently affected gene
in nemaline myopathy. To date, 64 different mutations in NEB
have been reported in nemaline myopathy probands (Pelin
et al., 1999; Lehtokari et al., 2006, 2009).
Nebulin is a giant sarcomeric protein (800 kDa); its C-terminus
is anchored in the Z-disk and its N-terminus is located close to the
thin filament pointed end. Thus, a single nebulin molecule spans
nearly the entire length of the thin filament (Fig. 1). Insights into
the role of nebulin’s functions made a leap forward when two full
nebulin knockout mouse models were published (Bang et al.,
2006; Witt et al., 2006). Nebulin plays important roles in sarco-
meric structure and contractile performance. It stabilizes the thin
filament and specifies its minimal length (Bang et al., 2006; Witt
et al., 2006; Castillo et al., 2009; Gokhin et al., 2009; Pappas
et al., 2010). Recent evidence also suggests that nebulin modu-
lates both the kinetics of actomyosin interaction (Bang et al.,
2009; Chandra et al., 2009) and the calcium sensitivity of force
generation (Chandra et al., 2009). Skeletal muscle fibres of pa-
tients with nemaline myopathy with NEB mutations might develop
muscle weakness due to loss of these functions of nebulin; their
myofibres contain shorter thin filaments (Ottenheijm et al.,
2009b), have altered crossbridge cycling kinetics (Ottenheijm
et al., 2010; Lawlor et al., 2011; Ochala et al., 2011), and their
calcium-sensitivity of force generation is reduced (Ottenheijm
et al., 2010). However, studies on muscle fibres from patients
are limited due to, for example, the small size of diagnostic
muscle biopsies and the heterogeneity of the study populations.
Consequently, our understanding of the mechanisms underlying
muscle weakness in patients with nemaline myopathy with nebulin
mutations remains incomplete. To improve this understanding re-
quires the development of mouse models that harbour mutations
in Neb that are found in patients.
Here, we have generated a mouse in which Neb exon 55 is
deleted (Fig. 1)—an in-frame deletion—to model a founder mu-
tation frequently seen in patients with nemaline myopathy and
which causes autosomal recessive nemaline myopathy (Anderson
et al., 2004; Lehtokari et al., 2006, 2009). This model
(NebExon55) allowed, for the first time, for a detailed and com-
prehensive investigation of the disease mechanisms caused by a
nebulin mutation and for the evaluation of potential treatments.
Our findings reveal that homozygous mice have a phenotype that
recapitulates important features observed previously in patients
with nemaline myopathy with deletion of NEB exon 55, including
severe muscle weakness and, importantly we show that muscle
strength can be restored by a novel fast skeletal troponin activator
that, at submaximal force levels, augments the response of the
thin filament to calcium.
Materials and methods
Generation of NebExon55 mice
NebExon55 mice were designed to mimic the 2502-bp deletion that
has previously been found to cause nemaline myopathy in humans
(Anderson et al., 2004). Note that Neb exon 55 is the murine equiva-
lent of the exon deleted in human patients (Kazmierski et al., 2003).
The construct replaced exon 55 and parts of introns 54 and 55 with a
flippase recognition target (FRT) flanked neomycin cassette. No differ-
ences in phenotype (life-span, body weight, and nebulin protein levels)
were found when the neomycin cassette was removed with a flippase
(FLP) deleter strain [B6; SJL-Tg(ACTFLPe)9205Dym/J- purchased from
Jackson Laboratories]. Animals were maintained on a C57/BL6 back-
ground. All experiments were approved by IACUC and followed the
NIH Guidelines ‘Using Animals in Intramural Research’ for animal use.
A targeting construct was assembled by cloning arms of homology
from C57/BL6 genomic DNA (purchased from Jackson Labs) into a
pCKOB vector. The vector was introduced into C57BL/6J-Tyrc-2J/J
embryonic stem cells by electroporation. The deletion was introduced
by homologous recombination and selected by negative selection
against thymidine kinase (using Ganciclovir) and positive selection
for neomyosin resistance (G418). The surviving embryonic stem
cell clones were verified by long PCR using primers (P1)
5’-ATTGACAATGCCGATTAACTACTGC-3’ and (P2) 5’-CTGGCACTC
TGTCGATACCC-3’ (left arm) (P3) 5’-ACACGCGTCACCTTAATATG
C-3’ and (P4) 5’-CCCAGCTGCTTACGGTAGCC-3’ and used to pro-
duce NebEx55 mice by injection into C57/BL6 blastocyst. Genotyping
was performed using tail digests using GoTaq Green Master
Mix (Promega). The following primer sets were used: (P5)-reverse
5’-GAAAGGAACTCTGTCCTCTGG-3’; (P6) WT forward
Figure 1 Top: Schematic of the location of nebulin in the
sarcomere. Bottom: Schematic of the nebulin protein. Nebulin
has a highly modular structure, within the central region
(M9-M162) seven modular repeats arranged into 22 super-
repeats. Exon 55 codes for 35 amino acids that are part of repeat
5 and 6 (super-repeat 9). Note that exon 55 in the human and
murine nebulin gene are equivalent.
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5’-GCATTCTTGCTCTTTCTTGTATGG-3’; (P3) NebEx55 forward
5’-ACACGCGTCACCTTAATATGC-3’; (P7) NebEx55 neo removed
forward 5’-ACACCCAGGCAGAAGCTAGG-3’.
Histochemistry and electron microscopy
Cross sections (5 mm) of isopentane-frozen quadriceps muscles were
taken midway down the length of the muscle and stained with
haematoxylin and eosin or Gomori trichrome using standard histo-
chemical techniques. For Gomori trichrome staining, sections were
stained in Harris haematoxylin (Richard Allen Scientific) for 5 min,
rinsed, and then stained in Gomori One-Step Light Green Solution
(Newcomer Supply) for 10 min. Following an additional rinse and dif-
ferentiation in 0.2% acetic acid (Newcomer Supply) for 2 min, sections
were dehydrated and coverslipped using standard techniques. Light
microscopic images were captured using an Olympus DP72 camera
and cellSens Standard software (Olympus). For the determination of
fibre size in quadriceps muscle sections, immunofluorescence was per-
formed using anti-dystrophin antibodies, and a representative area of
the muscle was photographed using a Zeiss ImagerZ1 microscope with
an Axiocam HRC camera. The minFeret diameter (the smallest diam-
eter across the myofibre) was measured manually in sections from four
wild-type mice (range 653 to 862 fibres measured) and three
NebExon55 mice (range 1003 to 1343 fibres measured) using Zeiss
Axiovision 4.8 software. For electron microscopy, glutaraldehyde-
fixed portions of tibialis cranialis muscle were submitted to the
Microbiology and Molecular Genetic Electron Microscopy Facility at
the Medical College of Wisconsin. Tissue was then fixed in 2.5%
glutaraldehyde in 0.1 M cacodylate buffer pH 7.4 for 60 min,
washed 3  10 min in 0.1 M cacodylate buffer, post-fixed with 1%
potassium ferrocyanide reduced OsO4 for 3 h on ice, dehydrated
through graded methanol, and embedded in EMbed 812 resin
(hard). Ultrathin sections (60 nm) were contrasted with uranyl acetate
and lead citrate and viewed in a Hitachi H600 TEM.
Gel electrophoresis and western
blotting
Gel electrophoresis of nebulin was with 1% agarose gels and has been
described in detail previously (Warren et al., 2003). Muscle samples
from 20 wild-type and 20 NebExon55 mice were flash frozen in liquid
nitrogen after dissection. Samples were pulverized to a fine powder,
solubilized and loaded on 1% agarose gels. Gels were then stained
with Coomassie blue and scanned using an Epson expressions scanner.
For western blots, samples were loaded in 0.8% SDS-agarose gels
and run at 15 mA/gel for 3 h. Gels were transferred onto 0.45 mm
polyvinylidene fluoride membranes (Imobilon) using a Bio-Rad semi-
dry transfer unit at 152 mA/gel for 2.5 h. Blots were stained using
Ponceau S to visualize total protein, dried and imaged. Blots were
then rehydrated, blocked with 50% Odyssey Blocking Buffer in PBS
for 1 h and incubated with Rabbit anti-nebulin N-terminus (Myomedix)
overnight. Primary antibody was then removed and CF680 goat
anti-rabbit secondary (Biotium Inc.) was added. Blots were scanned
and analysed using an Odyssey infrared imaging system (Li-Cor
Biosciences).
Nebulin transcriptional profiling
Day 4 longissimus dorsi muscle was isolated from wild-type and
NebEx55 mice and stored in RNAlater (Ambion). RNA was isolated
using RNeasy Fibrous Tissue Mini Kit (Qiagen). A custom microarray
was prepared by spotting 50-mer oligonucleotides in triplicate onto
GAPSII amino-silane coated slides (Corning) with a robotic arrayer
(Virtek). Oligonucleotide sequences for every murine nebulin exon
were selected with 45–55% GC content, Tm near 70
C, low self-
complementarity, and specificity based on NCBI BLAST searches with
no off-target stretches longer than 25 nt with identity greater than
80%; for exons shorter than 50 nt the selected sequence spans an
exon–exon junction. Sequence-specificity was confirmed by BLAT
against the current mouse genome (GRCm38/mm10). For optimizing
hybridization conditions, 5 bp mismatch controls were incorporated.
The array had been validated by analysing transcripts isolated from
human muscle with known nebulin exon composition. RNA was re-
verse transcribed and amplified using SenseAmp (Genisphere), and
SuperScript III (Invitrogen) and dye-coupled with Alexa Fluor 555
or AlexaFluor 647 (Invitrogen). Sample pairs were hybridized with
SlideHybTM Glass Array Hybridization Buffer #1 (Ambion) in a
GeneTAC Hybridization Station (Genomic Solutions); slides were
scanned with an ArrayWoRX scanner and the results analysed using
the R package CARMA (Greer et al., 2006).
Immunofluorescence confocal scanning
laser microscopy
Small muscle strips were dissected and permeabilized overnight at
4C in relaxing solution (in mM; 20 BES, 10 EGTA, 6.56 MgCl2,
5.88 NaATP, 1 DTT, 46.35 K-propionate, 15 creatine phosphate,
pH 7.0 at 20C) containing 1% (v/v) TritonTM X-100. Immunolabelling
and confocal scanning laser microscopy was performed as described
previously (Ottenheijm et al., 2009b). Primary antibodies: anti--acti-
nin (mouse monoclonal, A7811, Sigma-Aldrich), anti-tropomodulin-1
(Witt et al., 2006) Alexa Fluor 488 conjugated phalloidin (A12379,
Invitrogen), anti-CapZ (mouse monoclonal, 5B12.3, DSHB), and
rabbit anti-nebulin N-terminus (Myomedix). Secondary antibodies:
Alexa Fluor 594 (goat anti-mouse, Invitrogen), and Alexa Fluor
488 (goat anti-rabbit, Invitrogen). Secondary antibodies did not stain
when used without primary antibodies (data not shown). Images were
produced using a Bio-Rad MRC 1024 confocal laser scanning micro-
scope with the LaserSHARP 2000 software package (Hercules). From
the acquired images, thin filament lengths were determined using
ImageJ software (National Institutes of Health).
Permeabilized fibre contractility
For contractility experiments we used tibialis cranialis muscle; the
equivalent of m. tibialis anterior in humans, which has been shown
to be selectively affected in patients with nemaline myopathy with
nebulin mutations (Jungbluth et al., 2004). The procedures for per-
meabilized muscle fibre contractility were as described previously
(Ottenheijm et al., 2009a, b, 2010, 2011), with minor modifications.
In short, small strips dissected from muscle from six wild-type and six
NebExon55 mice were permeabilized, or skinned, overnight at 4C in
relaxing solution (in mM; 20 BES, 10 EGTA, 6.56 MgCl2, 5.88 NaATP,
1 DTT, 46.35 K-propionate, 15 creatine phosphate, pH 7.0 at 20C)
containing 1% (v/v) TritonTM X-100. The skinning procedure renders
the membranous structures in the muscle fibres permeable, which
enables activation of the myofilaments with exogenous Ca2 + .
Preparations were washed thoroughly with relaxing solution and
stored in 50% glycerol/relaxing solution at 20C. Small muscle
fibre bundles (diameter 0.07 mm) were dissected from the permea-
bilized strips, and were attached to a strain gauge and a high-speed
motor using aluminium foil clips. Experiments were performed at 20C.
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The XY (width) and XZ (depth, using a prism) dimensions of bundle
diameters were measured with a 40 objective. The muscle bundle
cross-sectional area was calculated from the average of three width
and depth measurements made along the length of the muscle bundle.
The preparation was activated at pCa 4.5 (pCa =  log of molar free
Ca2 + concentration) to obtain maximal Ca2 + -activated force. Maximal
tension was determined by dividing the force generated at pCa 4.5 by
cross-sectional area. To determine force–sarcomere length relations,
the maximal force generated at various sarcomere lengths was deter-
mined. Sarcomere length was measured with an on-line laser-diffrac-
tion system (Granzier and Wang, 1993).
To determine the force–pCa relation, muscle preparations were se-
quentially bathed in solutions with pCa values ranging from 4.5 to 9.0
and the steady-state force was measured. Measured force values were
normalized to the maximal force obtained at pCa 4.5. The obtained
force–pCa data were fit to the Hill equation, providing pCa50 (pCa
giving 50% maximal active tension) and the Hill coefficient, nH, an
index of myofilament cooperativity.
To determine a dose-response curve for the fast skeletal troponin
activator CK-2066260 (Cytokinetics Inc) tissue was exposed to pCa
solutions of 6.25 with increasing concentrations (1, 2, 5, 10 and
20 mM) of CK-2066260 dissolved in 1% dimethylsulphoxide (DMSO)
as vehicle. Note that 1% DMSO did not affect muscle fibre contractility
(data not shown). CK-2066260 enhanced submaximal force generation
with a maximal effect at 5 mM (data not shown), which is in accordance
with previously reported dose-response curves of its analogue CK-
2017357 (Russell et al., 2012). Accordingly, experiments were con-
ducted with either CK-2066260 (5mM) or vehicle alone (1% DMSO).
Force–pCa relations were determined as described above.
To measure the rate of tension redevelopment (ktr), we used the
large slack/release approach (Brenner and Eisenberg, 1986), to disen-
gage force generating crossbridges from the thin filaments, which
were isometrically activated. Three different bathing solutions were
used during the experimental protocols: a relaxing solution, a pre-
activating solution with low EGTA (ethylene glycol tetraacetic acid)
concentration, and an activating solution. The composition of these
solutions was as described previously (Stienen et al., 1996). Fast acti-
vation of the fibres was achieved by transferring the permeabilized
fibres from the pre-activation solution containing a low concentration
of EGTA (pCa 9.0) to a pCa 4.5 activating solution. Once the steady-
state was reached, a slack equivalent to 10% of the muscle length was
rapidly induced at one end of the muscle using the motor. This was
followed immediately by an unloaded shortening lasting 30 ms. The
remaining bound cross-bridges were mechanically detached by rapidly
(1 ms) restretching the muscle fibre to its original length, after which
tension redevelops. The rate constant of monoexponential tension re-
development (ktr) was determined by fitting the rise of tension to the
following equation: F = Fss(1  e-ktr.t), where F is force at time t and ktr
is the rate constant of tension redevelopment.
To determine force simultaneously with ATP consumption rate, we
used the system described by Stienen et al. (1996). To measure the
ATPase activity, a near UV light was projected through the quartz
window of the bath (30 ml volume and temperature controlled at
20C) and detected at 340 nm. The maximum activation buffer (pCa
4.5) contained 10 mM phosphoenol pyruvate, with 4 mg/ml pyruvate
kinase (500 U/mg), 0.24 mg/ml lactate dehydrogenase (870 U/mg)
and 20 mM diadenosine-5’ pentaphosphate (A2P5). For efficient
mixing, the solution in the bath was continuously stirred by means
of motor-driven vibration of a membrane positioned at the base of
the bath. ATPase activity of the permeabilized fibre bundles was mea-
sured as follows: ATP regeneration from ADP is coupled to the break-
down of phosphoenol pyruvate to pyruvate and ATP catalysed by
pyruvate kinase, which is linked to the synthesis of lactate catalysed
by lactate dehydrogenase. The breakdown of NADH, which is propor-
tional to the amount of ATP consumed, is measured online by UV
absorbance at 340 nm. The ratio of light intensity at 340 nm (sensitive
to NADH concentration), and the light intensity at 410 nm (reference
signal), is obtained by means of an analogue divider. After each re-
cording, the UV absorbance signal of NADH was calibrated by multiple
rapid injections of 0.25 nmol ADP (0.025 ml of 10 mM ADP) into the
bathing solution, with a stepper motor-controlled injector. The slope of
the [NADH] versus time trace during steady-state tension development
of a calcium-induced contraction (Fig. 8B) was determined from a
linear fit and the value divided by the fibre volume (in mm3) to de-
termine the fibre’s ATPase rate. ATPase rates were corrected for the
basal ATPase measured in relaxing solution. The ATPase rate was
divided by tension (force/cross-sectional area) to determine the ten-
sion cost.
Myofibril contractility
Myofibrils were prepared from flash frozen and then thawed tibialis
cranialis muscles from 4–7 day old wild-type (n = 5) and and homozy-
gous NebExon55 (n = 5) mice, and placed in ice-cold rigor solution
containing (mM): NaCl 132, KCl 5, MgCl2 1, Tris 10, EGTA 5 (pH
7.1). The muscles were incubated for 3 h in the same solution with
1% TritonTM-100. Triton was then removed and the muscles sheared
in rigor solution to produce myofibril suspensions. In the present ex-
periments we used previously published techniques (Tesi et al., 2002).
Briefly, to study myofibrillar force development a small volume of the
myofibril suspension was transferred to a temperature-controlled
chamber (15C) filled with relaxing solution (pCa 8.0) and mounted
on an inverted microscope. Single myofibrils or bundles of few myo-
fibrils (25–80 mm long, 1–4 mm wide) were mounted horizontally be-
tween two glass microtools. One tool was connected to a length-
control motor that could produce rapid (51 ms) length changes. The
second tool was a calibrated cantilevered force probe (2–6 nm/nN;
frequency response 2–5 kHz). Force was measured from the deflection
of the image of the force probe projected on a split photodiode.
Average sarcomere length and myofibril diameter were measured
from image analysis. The initial sarcomere length of the preparations
was adjusted to 2.2 mm. Myofibrils were activated and relaxed by
rapidly translating the interface between two flowing streams of dif-
ferent pCa solutions across the length of the preparation. The solution
change took place with a time constant of 2–3 ms and was complete in
5 5 ms. Activating and relaxing solutions, calculated as previously
described (Tesi et al., 2002), were at pH 7.0 and contained 10 mM
total EGTA (CaEGTA/EGTA ratio set to obtain pCa 8.0 and 4.5), 5 mM
MgATP, 1 mM free Mg2 + , 10 mM MOPS, propionate and sulphate to
adjust the final solution to an ionic strength of 200 mM and monova-
lent cation concentration of 155 mM. Creatine phosphate (10 mM) and
creatine kinase (200 U/ml) were added to all solutions. Contaminant
inorganic phosphate (Pi) from spontaneous breakdown of MgATP and
creatine phosphate was reduced to 55 mM by an inorganic phosphate
scavenging system (purine-nucleoside-phosphorylase with substrate 7-
methyl-guanosine). All solutions to which the muscles and myofibrils
were exposed contained a cocktail of protease inhibitors including leu-
peptin (10mM), pepstatin (5 mM), PMSF (200 mM) and E64 (10 mM), as
well as NaN3 (500 mM) and DTE (2 mM).
Statistical analyses
Data are presented as mean  SEM. For statistical analyses, t-tests
were used. The effect of CK-2066260 was investigated within
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individual muscle fibre preparations; a paired t-test was performed in
these analyses. P5 0.05 was considered to be statistically significant.
Results
NebExon55 mice display a phenotype
that resembles nemaline myopathy
Using homologous recombination, we removed exon 55 from the
nebulin gene. Mice heterozygous for the targeted allele are viable
and fertile and survive into adulthood with no obvious clinical or
contractile phenotype. Homozygous offspring (referred to as
NebExon55) are produced at expected Mendelian genetic ratios
(1/4 of total number of pups using heterozygous breedings,
Fig. 2A), with a weight at birth that is not different from that of
heterozygous and wild-type littermates. However, NebExon55
mice show severe growth retardation after birth (Fig. 2B) and
typically do not survive past the first week (Fig. 2C).
Nemaline myopathy in humans is characterized by the presence
of nemaline bodies (often called nemaline rods when they are rod-
shaped), which is often accompanied by myofibre hypotrophy. To
test whether these histological characteristics of nemaline myop-
athy are present in NebExon55 mice, we first evaluated sections of
quadriceps muscle stained with haematoxylin and eosin or Gomori
trichrome. As shown in Fig. 3A, the haematoxylin and eosin
stained sections from 6-day-old wild-type and NebExon55 mice
reveal smaller muscle fibres in NebExon55 mice. Quantitative ana-
lysis revealed that where average fibre minFeret diameter was
13.0  0.4 mm in wild-type mice; this was significantly reduced
to 10.1  0.3 mm in NebExon55 mice (P50.01). Discrete popula-
tions of large and small fibres were not observed in NebExon55
mouse muscle. The number of central nuclei was 51% in both
wild-type and NebExon55 muscle, and NebExon55 muscle showed
no signs of fibrosis. Nemaline bodies were not visible at the light
microscopic level on Gomori trichrome stain (Fig. 3A, lower panel)
Figure 2 (A) Homozygous (NebExon55) mice are born close to Medelian ratio: 13 homozygous mice out of total 57 pups when using
heterozygous breedings. (B) Body weight of NebExon55 mice at birth is not different from that of HET and wild-type (WT) littermates.
NebExon55 mice show severe growth retardation after birth, and (C) typically do not survive past the first week (survival curve based on
57 pups). Inset: Photograph of a NebExon55 (HOM) and a wild-type littermate mouse illustrating the growth retardation in NebExon55
mice.
Figure 3 Histological findings in 6-day-old wild-type and
NebExon55 mice. Haematoxylin and eosin (H&E) stained sec-
tions of quadriceps muscle from wild-type (wt) and NebExon55
mice reveal smaller muscle fibres in NebExon55 mice. Nemaline
rods were not visible at the light microscopic level on Gomori
trichrome stain, but electron-dense nemaline bodies (arrows)
were seen on electron microscopy (EM) in the tibialis cranialis
muscle from all NebExon55 mice. Nemaline bodies were not seen
in wild-type mouse muscle. Scale bar = 40mm for haematoxylin
and eosin and Gomori trichrome images, 2 mm for 5000
electron microscopy images, and 500 nm for the 30 000
electron microscopy image.
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of quadriceps muscle, but electron microscopy revealed electron-
dense nemaline bodies at the location of the Z-band (arrows, Fig.
3B) in the tibialis cranialis (the murine equivalent of tibialis anterior
in humans) muscles of NebExon55 mice. These nemaline bodies
displayed electron density equivalent to normal Z-bands, which
differentiates them from the Z-band streaming that can be
found in a variety of muscle disorders. Nemaline bodies were
not seen in wild-type mouse muscle. Thus, NebExon55 mice dis-
play a histological phenotype that resembles nemaline myopathy,
including the presence of nemaline bodies and hypotrophic fibres.
Deletion of exon 55 results in severely
reduced nebulin protein levels
NEB exon 55 encodes 35 amino acids and represents 4 kDa at
the protein level. As deletion of exon 55 maintains the reading
frame 3’ of exon 55, we expected the NebExon55 mice to express
a nebulin isoform that is 4 kDa smaller than wild-type nebulin.
However, SDS-agarose gel analysis showed that, in 5-day-old
NebExon55 mice, nebulin proteins levels were severely reduced
in all muscle types tested (Fig. 4A). Western blot experiments
using an antibody directed against the nebulin N-terminus con-
firmed these findings (Fig. 4B). To evaluate whether the low
nebulin protein levels at Day 5 after birth were preceded by a
gradual decrease from normal levels at birth, we also evaluated
nebulin levels at Day 1 after birth (Fig. 4C) and at embryonic Day
19 (Fig. 4D). These experiments showed that nebulin protein
levels were severely reduced in NebExon55 muscle at both time
points. Nebulin protein levels in NebExon55 quadriceps muscle
(normalized to myosin heavy chain) was 10% of wild-type
values in embryonic Day 19 tissue, 8% of wild-type values in
post-natal Day 1 tissue, and decreased to 2% of wild-type
values in post-natal Day 5 tissue (Fig. 4E). Thus, deletion of
exon 55 results in severly reduced nebulin protein levels.
To evaluate whether the reduced nebulin protein levels were
caused by alterations at the level of DNA transcription or of mes-
senger RNA translation, we used a homemade nebulin exon
microarray to test which of the 166 murine nebulin exons are
included in the full-length nebulin messenger RNA. As shown in
Fig. 5, in addition to the expected reduction of exon 55 messenger
RNA, transcription of nearly all nebulin exons was significantly
reduced in NebExon55 muscle. Thus, these results suggest that
the low nebulin protein levels in NebExon55 mice are not caused
by defects in the translation of nebulin messenger RNA into pro-
tein but rather by changes in transcription of the mutant nebulin
gene or in the stability of the mutant nebulin messenger RNA.
Figure 4 (A) SDS-agarose gel electrophoresis reveals severely reduced nebulin protein levels in NebExon55 mice in all skeletal muscle
types tested, whereas myosin heavy chain (MHC) and titin levels are unaltered. Muscles are obtained from 5-day-old mice.
(B) Quantitative western blotting studies with an antibody against nebulin’s N-terminus shows that nebulin protein levels are 2% of
wild-type (wt) levels. Western blotting studies with the same antibody on muscle from embryonic Day 19 (E19) mice (C) and 1-day-old
(P1) mice (D) and show that nebulin protein is 10% of wild-type values at Day 19 (E19) and 8% of wild-type values at Day 1
(E). *P5 0.05. Quad = m. quadriceps; EDL = extensor digitorum longus; Psoas = m. psoas major; Diaph = m. diaphragm; Long = m.
longissimus dorsi; Pect = m. pectoralis major; Gast = m. gastrocnemius.
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NebExon55 mice have shorter thin
filament lengths
Nebulin plays an important role in specifying thin filament length,
and shorter thin filaments clearly contribute to reduced sarcomeric
force generation in human nebulin-deficient nemaline myopathy
(Ottenheijm et al., 2009b). Therefore, we measured thin filament
length in NebExon55 muscle fibres. Using immunofluorescence
confocal scanning laser microscopy we determined the location
of tropomodulin (a thin filament pointed end capping protein)
relative to the Z-disk and we measured the width of the band
obtained using the fluorescently labelled actin-binding protein
phalloidin.
Figure 6A shows that the staining pattern of fluorescently
labelled phalloidin differed between myofibrils from NebExon55
and wild-type tibialis cranialis muscle; wild-type myofibrils
showed broad actin labelling with uniform intensity (except for
the Z-disk area where actin filaments overlap), whereas in
NebExon55 myofibrils the labelling was narrower, and intensity
gradually decreased from the Z-disk towards the middle of the
sarcomere. Densitometric analysis revealed that the width at
half-maximal intensity was 2.25  0.03mm for wild-type and
1.75  0.01 mm for NebExon55 myofibrils (Fig. 6A).
Tropomodulin staining in wild-type myofibrils showed a distinct
doublet in the middle of the sarcomere, 2.03  0.03mm apart,
measured across the Z-disk, whereas in myofibrils from
NebExon55 mice this value was only 1.67  0.03 mm (Fig. 6B).
These findings support the results from the phalloidin experiments
and suggest that thin filament lengths are reduced from 1.0 mm
in wild-type myofibrils to 0.85mm in NebExon55 myofibrils.
The experiments with fluorescently labelled tropomodulin re-
vealed that thin filaments are shorter in NebExon55 myofibrils
and suggested that capping at the thin filament pointed end by
tropomodulin remains intact in these myofibrils. Immuno-
fluorescence experiments on CapZ (a thin filament barbed end
capping protein) showed that capping at the barbed end also
remains intact in NebExon55 myofibrils (Fig. 6C).
Finally, the data in Fig. 6D, in which an antibody against neb-
ulin’s N-terminus was used, show that nebulin is nearly absent
from NebExon55 myofibrils, thereby confirming the western blot
experiments (Fig. 4). Thus, immunofluorescence confocal micros-
copy experiments show that in NebExon55 muscle thin filament
capping is intact but that thin filament length is significantly
reduced.
NebExon55 mice display severe muscle
weakness
Force–sarcomere length relation
Because sarcomeres generate force in proportion to thick and thin
filament overlap, a well-defined thin filament length is an import-
ant determinant of muscle function. This is illustrated by the force–
sarcomere length relationship, which is characterized by a force
plateau at optimal filament overlap, followed by a descending limb
at higher sarcomere lengths as filament overlap decreases.
Shortened thin filaments will reduce thick and thin filament
Figure 5 Microarray-based gene expression analysis of nebulin exon expression of m. longissimus dorsi in NebExon55 mice compared
with wild-type (wt) mice at 4 days of age. The array contains all 166 murine nebulin exons. Nearly all nebulin exons are downregulated in
NebExon55 mice.
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overlap and impair the sarcomere’s force generating capacity,
which is reflected by a leftward shift of the force–sarcomere
length relationship (Granzier et al., 1991). Hence we studied
whether the reduced thin filament length in NebExon55 myofibrils
affects the force generating capacity of muscle by determining the
force–sarcomere length relationship in permeabilized fibre prepar-
ations. Fibres from wild-type muscle showed a characteristic force
plateau up to a sarcomere length of 2.6 mm, followed by a linear
descending limb (Fig. 7A). Note that the descending limb of wild-
type fibres intercepts the x-axis at 3.6 mm. Assuming that thick
filaments are constant at 1.6 mm, this would suggest that thin
filament length is 1.0 mm, which is in-line with thin filament
lengths as determined by our confocal microscopy studies (Fig.
6A and B). Importantly, fibres from NebExon55 muscle showed a
leftward-shift of the force–sarcomere length relationship, indicat-
ing shorter thin filament lengths (Fig. 7A). The descending limb of
NebExon55 fibres intercepts the x-axis at a sarcomere length of
3.4 mm, a length that is consistent with thin filament lengths of
0.9 mm, which is close to the length as determined by the con-
focal microscopy studies (0.85 mm).
Considering that thin filament length is an important determin-
ant of a muscle’s force generating capacity, we also plotted
tension (force normalized to fibre cross-sectional area) versus
sarcomere length (Fig. 7B). Importantly, at a sarcomere length
of 2.4 mm, a length on the plateau of the force–sarcomere
length relation of both genotypes, absolute maximal tension was
reduced in fibres from NebExon55 muscle to 38% of wild-type
values (Fig. 7B). To study whether the reduced maximal tension of
NebExon55 fibres is caused by a reduction in myofibrillar fractional
area or rather by changes in myofibrillar function, we also deter-
mined the contractile force of single myofibrils isolated from
NebExon55 and wild-type muscle fibres. As shown in Fig. 7C,
the maximal tension generated by NebExon55 myofibrils was
reduced to 36% of wild-type values, a reduction that is similar
in magnitude to that observed in NebExon55 fibres. Thus, these
findings indicate that muscle from NebExon55 mice is significantly
weakened, that this weakening is primarily caused by changes in
myofibrillar function, and that reduction of thin filament length
contributes to weakness especially at longer sarcomere lengths.
Crossbridge cycling kinetics
Recent work has led to the notion that nebulin is important for the
tuning of crossbridge cycling kinetics to maximize force generation
(Chandra et al., 2009; Ottenheijm and Granzier, 2010). To
Figure 6 (A) Left: Actin staining with phalloidin-Alexa Fluor 488 in Day 6 tibialis cranialis myofibrils from NebExon55 and wild-type mice
shows broad staining in wild-type myofibrils (top), whereas this staining is narrowed in NebExon55 myofibrils (bottom). Right: Analysis of
phalloidin line scan intensities revealed significantly reduced average thin filament lengths in NebExon55 myofibrils. (B) Left: NebExon55
and wild-type myofibrils stained for -actinin and tropomodulin (Tmod1). Right: Overlay of line scan intensity profile of -actinin and
tropomodulin. The distance between tropomodulin staining (measured across the Z-disk, and indicated as Tmod--actinin-Tmod) is
significantly reduced in NebExon55 myofibrils. (C) CapZ staining of NebExon55 and wild-type myofibrils. Staining of NebExon55 myofibrils
is similar to the staining pattern of wild-type myofibrils. (D) Left: Six day old NebExon55 and wild-type myofibrils stained for -actinin and
nebuln’s N-terminus (Neb N). Right: Analysis of line scan intensities. Note that Neb N staining is nearly absent in NebExon55 myofibrils.
*P5 0.05.
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determine whether changes in crossbridge cycling kinetics contrib-
ute to the weakness observed in NebExon55 fibres, we determined
the tension cost and the rate constant of force redevelopment, ktr,
in fibres from NebExon55 muscle and compared results to those
from wild-type muscle. To determine ktr, fibres were first isomet-
rically activated at pCa 4.5 and when a steady force was reached,
crossbridges were disengaged by performing a quick release, a
brief period of unloaded shortening, and then a rapid restretch
to the original length. Following restretch, force rebuilds with a
time course that can be fit to a monoexponential with rate con-
stant ktr (see Fig. 8A, left panel, for a typical force response). As
shown in Fig. 8A, ktr was significantly lower in the Neb
Exon55
fibres than in the wild-type fibres (4.3  0.5 versus
5.9  0.3 s1, NebExon55 versus wild-type, respectively). Tension
cost was determined by the simultaneous measurement of the
breakdown of NADH and force during contraction, with NADH
levels enzymatically coupled to ATP utilization (see ‘Materials and
methods’ section). An example of a maximally-activated
NebExon55 fibre preparation with [NADH] falling linearly during
the tension plateau is shown in Fig. 8B. The slope of the [NADH]
versus time curve was normalized by the fibre volume to obtain
ATP consumption rates that can be compared for differently sized
muscle preparations. By normalizing ATP consumption rates to the
tension generated and fibre volume, the tension cost can be deter-
mined. As shown in Fig. 8B, the tension cost was significantly
higher in NebExon55 fibres compared with wild-type fibres
(10.4  1.1 versus 6.4  0.4 pmol/mN/mm/s, NebExon55 versus
wild-type, respectively).
Next, we determined the activation and relaxation kinetics of
single myofibrils isolated from NebExon55 and wild-type muscle
fibres. Due to their small size (diameter: 1–2mm) and when com-
bined with a rapid solution switching mechanism (Tesi et al.,
2002) force activation and relaxation kinetics can be determined.
As shown in Fig. 8C and D, the rate constants of activation (kact)
and of force redevelopment following a rapid-release rapid-
restretch protocol (ktr) were significantly reduced in Neb
Exon55
myofibrils; kact: 1.46  0.07 versus 2.89  0.21 s-1, NebExon55
versus wild-type, respectively; ktr: 2.27  0.16 versus
3.29  0.25 s-1, NebExon55 versus wild-type, respectively. Note
that the magnitude of ktr reduction in myofibrils was in the
same order as observed in NebExon55 fibres. The relaxation
phase of myofibrils consists of an initial slow phase for which
we determined the rate constant ‘slow krel’ – which is thought
to reflect the apparent rate constant of detachment of force bear-
ing crossbridges, gapp (tension cost is also proportional to gapp)
(Poggesi et al., 2005). The subsequent fast relaxation phase is
characterized by the ‘fast krel’. Force relaxation kinetics in the
NebExon55 myofibrils were significantly faster than in wild-type
myofibrils: slow krel: 1.17  0.15 versus 0.56  0.05 s-1,
NebExon55 versus wild-type, respectively; fast krel: 11.0  1.5
versus 6.0  0.04 s-1 NebExon55 versus wild-type, respectively
(Fig. 8D). Note that the magnitude of increase in slow krel in
Figure 7 (A) The force–sarcomere length relation of tibialis cranialis fibres from 6-day-old NebExon55 and wild-type (wt) mice, with force
normalized to maximal force at the optimal length: the relation is shifted leftward in NebExon55 fibres suggesting shorter thin filaments in
NebExon55 fibres. (B) Top: The maximal tension–sarcomere length relation of NebExon55 and wild-type fibres, illustrating that NebExon55
fibres develop at all sarcomere lengths a reduced level of force. This indicates that other factors, in addition to shorter thin filaments,
contribute to the weakness of NebExon55 muscle. Bottom: At a sarcomere length of 2.4 mm, maximal tension is reduced in fibres from
NebExon55 muscle to 38% of wild-type values. (C) Left: Force tracing of activated single myofibrils from wild-type and NebExon55
muscle. Right: Maximal tension of NebExon55 myofibrils is reduced to 36% of wild-type values.
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NebExon55 myofibrils is close to that of the increase in tension
cost in fibres.
Thus, these mechanical studies on both fibres and single myo-
fibrils show that crossbridge cycling kinetics are significantly
altered in muscle from NebExon55 mice.
Calcium sensitivity of force
The calcium sensitivity of force generation is also an important par-
ameter of muscle function as it reflects the response of force to
submaximal activation levels, levels at which muscle typically oper-
ates in vivo. To determine the calcium sensitivity of force, permea-
bilized fibres from tibialis cranialis muscle were exposed to
incremental calcium concentrations and the force response was re-
corded. As shown in Fig. 9A, the force–pCa curve of NebExon55
fibres was shifted rightward (reflected by a lower pCa50 in
NebExon55 fibres: 6.22  0.02 versus 6.34  0.01, NebExon55
versus wild-type, respectively), indicating that the calcium sensitivity
of force was significantly reduced in fibres from NebExon55 mice
compared to those from wild-type mice. The cooperativity of acti-
vation (nH) was not different between groups. Thus, the calcium
sensitivity of force is reduced in NebExon55 muscle.
Next, we studied the ability of the novel compound CK-2066260
to restore the calcium sensitivity of force in NebExon55 fibres from
tibialis cranialis muscle. CK-2066260 is a recently developed skeletal
muscle troponin activator that amplifies the response of the thin
filament to calcium in fast skeletal muscle fibres (Russell et al.,
2012). As shown in Fig. 9B, 5 mM of CK-2066260 induced a
profound increase in the pCa50, an increase that was comparable
between NebExon55 and wild-type fibres (pCa50: 0.26  0.03
versus 0.29  0.02, NebExon55 versus wild-type, respectively).
Importantly, in NebExon55 fibres, CK-2066260 increased active
tension at submaximal (Ca2 + ) to values that exceeded those of
untreated wild-type fibres (Fig. 9C). These findings show the prom-
ise of fast skeletal troponin activation in restoring muscle strength
in nebulin-based nemaline myopathy.
Discussion
We generated the first mouse model for nebulin-based nemaline
myopathy by targeted deletion of Neb exon 55. Our findings
show that muscle from NebExon55 mice is severely weakened
Figure 8 (A) ktr measurements in 6-day-old Neb
Exon55 and wild-type (wt) fibres. Left: Example of a ktr protocol in a Neb
Exon55 fibre
preparation; right: ktr is significantly lower in Neb
Exon55 compared with wild-type fibres. (B) Tension cost measurements in NebExon55
and wild-type fibres. Left: Example of maximally activated NebExon55 fibres with developed force at the bottom and [ATP] at the top. The
slope of the [ATP] versus time trace was divided by fibre volume (in mm3) to determine ATP consumption rate. ATP consumption rate was
normalized to tension to determine the tension cost. Right: Tension cost is significantly higher in NebExon55 compared to wild-type fibres.
(C) An example of a protocol to determine crossbridge cycling kinetics in a myofibril. Myofibrils are rapidly activated (pCa 4.5), followed
by rapid relaxation (pCa 8.0) after steady state tension is reached. From the force tracings, the rate constants of activation (kact) and
relaxation are determined. Relaxation consists of an initial slow phase (slow krel) followed by a fast phase (fast krel). ktr is determined during
a separate protocol that is similar to that applied on fibres. (D) Both kact and ktr are significantly lower in Neb
Exon55 compared with wild-
type myofibrils, whereas slow and fast krel are significantly higher in Neb
Exon55 compared with wild-type myofibrils.
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and contains nemaline rods, both hallmark features of nemaline
myopathy. The muscle weakness in NebExon55 mice is caused by
hypotrophy of muscle fibres, and by the muscle fibres having
shorter thin filaments, changes in crossbridge cycling kinetics and
reduced calcium sensitivity of force generation. A novel drug that
facilitates calcium binding to the thin filament significantly aug-
mented muscle force to levels that exceed those observed in un-
treated control muscle. As we discuss in detail below, the overall
phenotype of this new mouse model recapitulates important fea-
tures observed previously in patients with nemaline myopathy with
deletion of Neb exon 55.
Deletion of exon 55 leads to severely
reduced nebulin protein levels
Nebulin is a giant protein expressed at high levels in skeletal
muscle. Most of the molecule is comprised of centrally located
modules (M9 to M162) that are organized into seven-module
super-repeats that match the repeat of the actin filament
(Fig. 1). This precise arrangement is thought to allow each nebulin
module to interact with a single monomer of the actin filament
(Labeit et al., 1991; Labeit and Kolmerer, 1995), and each nebulin
super-repeat to associate with a single tropomyosin (Tm)/troponin
(Tn) complex (Jin and Wang, 1991; McElhinny et al., 2003; Ogut
et al., 2003). NEB exon 55 encodes 35 amino acids that are part
of modules 69 and 70 in super-repeat 9 (Fig. 1). The absence of
exon 55 in the nebulin transcript does not generate a frameshift,
and the transcript is predicted to encode a protein that is 35 amino
acids smaller than the normal gene product. However, as two of
the encoded 35 amino acid modules of nebulin are interrupted by
the deletion of exon 55, this results in the disruption of the seven-
module set of super-repeat 9 (Labeit and Kolmerer, 1995). It has
been proposed that this disruption causes a mismatch between
nebulin and its binding sites on actin (Anderson et al., 2004),
thereby preventing the incorporation of mutant nebulin molecules
and leading to their degradation (Ottenheijm et al., 2009b). In line
with this proposition, a study on five patients homozygous for
deletion of NEB exon 55 showed that the muscle fibres of these
patients have nebulin levels that are 515% of normal values
(Ottenheijm et al., 2009b). The present work shows that nebulin
protein was severely reduced in all muscle types tested from
NebExon55 mice, including in embryonic muscle (Fig. 4), suggest-
ing that muscle loading after birth did not greatly accelerate the
loss of nebulin protein. Hence, the proteomic phenotype of
NebExon55 mice resembles that of the full nebulin knockout
models (Bang et al., 2006; Witt et al., 2006), although nebulin
protein levels in the NebExon55 mice are slightly higher and more
similar to those observed in patients (Ottenheijm et al., 2009b).
The nebulin exon microarray studies (Fig. 5) revealed the down-
regulation of nearly all nebulin exons at the RNA level, not only
exon 55. Thus, the low nebulin protein levels appear to be caused
by defects at the transcript level, rather than by degradation of
mutant nebulin protein. The mechanisms underlying the more
severe reduction of nebulin levels in NebExon55 mice compared
to humans with the same mutation is unclear. An explanation
could be that most patients with NEB exon 55 deletion also
have very little nebulin protein and that they die in utero.
However, the rate of miscarriage in the families that carry the
NEB exon 55 mutation appears to be within the normal range
(Beggs et al., in preparation) making this explanation unlikely.
Alternatively, nebulin isoform composition might play a role: if
inclusion of exon 55 is mandatory in the mouse and less so in
humans, then this would more severely affect nebulin protein
levels in NebExon55 mice. Transcript studies in the mouse
showed no differential splicing of exon 55 (Buck et al., 2010),
consistent with the absence of nebulin expression in any of the
muscle types that we studied (Fig. 4A and B). Thus if alternative
splicing of human nebulin transcripts were to occur that can pro-
duce some functional nebulin isoforms devoid exon 55, this could
explain why nebulin levels in NebExon55 mice are more severely
reduced than in humans with the same mutation.
Severe weakness of muscle fibres
caused by thin filament dysfunction
A hallmark feature of patients with nemaline myopathy is muscle
weakness, greatly affecting daily life activities and negatively im-
pacting the quality of life (North et al., 1997). At the structural
level, nemaline myopathy is characterized by myofibrillar disarray
Figure 9 (A) Force–Ca2 + characteristics of tibialis cranialis fibres
from 5-day-old NebExon55 and wild-type mice. Left: Note the
rightward shift of the force–pCa relationship in NebExon55
compared with wild-type fibres. Middle: The Ca2 + concentra-
tion needed for 50% of maximal force generation was signifi-
cantly higher (i.e. lower pCa50) in Neb
Exon55 versus wild-type
fibres, whereas no difference was found in the Hill coefficient
(nH, right). (B) The effect of the fast troponin activator CK-
2066260 on the force–Ca2 + characteristics in NebExon55 and
wild-type fibres. Left: 5 mM of CK-2066260 induced a large
increase in the pCa50, an increase that was comparable between
NebExon55 and wild-type fibres. Right: In NebExon55 fibres,
5 mM CK-2066260 increased active tension at submaximal
(Ca2 + ) to values that exceeded those of untreated wild-type
fibres. NS = not significant.
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originating from the Z-disk and culminating in nemaline rods,
which consist of thin filament and Z-disk proteins (Engel and
Gomez, 1967; Yamaguchi et al., 1978, 1982; Morris et al.,
1990; North, et al., 1997; Sanoudou and Beggs, 2001).
Importantly, the number of nemaline rods in muscle biopsies
does not correlate with muscle weakness in patients with nemaline
myopathy (Shimomura and Nonaka, 1989; Ryan et al., 2003). This
suggests that myofibrillar disarray and nemaline rods are a second-
ary phenotype and are not the sole contributors to the muscle
weakness associated with nemaline myopathy. The NebExon55
model has a relative paucity of rod bodies yet muscle weakness
is severe, supporting the notion that muscle weakness in nemaline
myopathy with nebulin mutations is caused primarily by changes
in myofilament function.
The maximal tension generated by muscle fibres from
NebExon55 mice was severely reduced (Fig. 7B and 9B), and
based on electron microscopy studies this reduction is unlikely to
be due to myofibrillar disarray (Fig. 3B). This conclusion is sup-
ported by the studies on the maximal tension generation of single
myofibrils (Fig. 7C): the magnitude of tension reduction in
NebExon55 myofibrils was similar to that in NebExon55 fibres
(62% and 64%, respectively). Thus, the weakness of muscle
fibres in NebExon55 mice can be attributed to changes in myofi-
brillar function, rather than by myofibrillar disarray or by a reduced
myofibrillar fractional area. Note that the maximal tension gener-
ated by myofibrils was higher than that by muscle fibres, both in
wild-type and NebExon55 mice, and that this is caused by the
tension in fibres being normalized to a cross-sectional area that
comprises myofibrils plus non-contractile material such as mito-
chondria, glycogen granules and sarcoplasmic reticulum. The
64% reduction in tension generation by fibres from NebExon55
muscle, combined with the reduction in fibre diameter of 23%,
results in a total force loss of 480% in NebExon55 fibres when
compared with wild-type fibres. This severe muscle fibre weakness
in NebExon55 mice explains why the mice die within several days
of birth, as this will severely hamper both feeding (the stomachs of
NebExon55 mice are typically devoid of milk) and breathing. That
many patients homozygous for deletion of NEB exon 55 have
been shown to survive past the neonatal phase (Anderson et al.,
2004; Lehtokari et al., 2006, 2009; Ottenheijm et al., 2009b,
2010) is likely to be partly due to the extensive medical care
that includes gastro-nasal feeding and mechanical ventilation. It
should be noted that some patients with deletion of NEB exon
55, those with the typical form of nemaline myopathy, remain
ambulant into adolescence or beyond. Future studies should ad-
dress whether these patients have higher nebulin protein levels
and a better preserved myofibrillar function.
The reduction in tension that we found in the mouse might be
due to any of the myofibrillar functions that nebulin has been
proposed to play: (i) specifying thin filament length; (ii) regulating
the interaction between myosin-based crossbridges and the thin
filament; and (iii) tuning the response of the thin filament to cal-
cium (Bang et al., 2009; Chandra et al., 2009; Ottenheijm and
Granzier, 2010;). Our work on the NebExon55 mice indicates that
all three mechanisms are disturbed upon deletion of Neb exon 55,
and contribute to the development of muscle weakness.
In skeletal muscle, thin filament lengths are fine-tuned at 1.1–
1.3 mm (depending on species and muscle type) (Littlefield and
Fowler, 2008) to overlap with thick filaments and to meet the
muscle’s contractile requirements (Burkholder et al., 1994;
Littlefield and Fowler, 2008). The extent of overlap between
thick and thin filaments determines the sarcomere’s force generat-
ing capacity: short thin filaments reduce overlap and impair force
generation. Thus, thin filament length is a key aspect of muscle
function, and recent work indicates that nebulin is involved in
specifying this length (Bang et al., 2006; Witt et al., 2006). Our
immunofluorescence confocal microscopy studies revealed that
thin filament length is significantly reduced from 1.0mm in wild-
type muscle to 0.85 mm in NebExon55 muscle. These structural
studies were corroborated by mechanical studies, which revealed
a leftward shift (at sarcomere lengths of 2.4 mm and longer) of the
force–sarcomere length relation in NebExon55 muscle fibres. Thus,
deletion of Neb exon 55 results in shorter thin filament lengths,
contributing to muscle weakness at longer sarcomere lengths.
Weakness of NebExon55 fibres was also apparent at sarcomere
lengths shorter than 2.4 mm (Fig. 7B), suggesting that the reduc-
tion of thin filament length is not the only mechanism for weak-
ness in NebExon55 mice. Our findings show that crossbridge
cycling kinetics in NebExon55 fibres are altered, and that this con-
tributes to muscle weakness. NebExon55 muscle fibres had signifi-
cantly higher tension cost compared to wild-type fibres (Fig. 8B),
which indicates that the crossbridge detachment rate is higher
(Stienen et al., 1996). In combination with the observation that
ktr was slower in Neb
Exon55 fibres (Fig. 8A), these findings lead to
the conclusion that the rate of crossbridge attachment is slower in
NebExon55 fibres. Consequently, the fraction of force generating
crossbridges is significantly reduced in NebExon55 muscle.
Importantly, these findings on NebExon55 fibres were strongly
supported by results from studies on single myobrils (Fig. 8C
and D). The advantages of studies on myofibrils include that,
due to their small size, they instantly equilibrate with the bathing
solution making it possible to study force relaxation kinetics.
Furthermore, as myofibrillar damage typically results in breakage
of the myofibrils during activation, the data obtained from myo-
fibrils reflect direct effects of the mutated protein on crossbridge
cycling kinetics without potential confounding effects of myofibril-
lar damage. Importantly, the magnitude of the ktr changes in
myofibrils were similar to that in fibres and the changes in slow
krel of myofibrils are similar to that of the tension cost measured in
fibres. Thus, measurement at two distinct levels of organization
(myofibrils and fibres) and using distinct techniques (tension cost
measurements and force relaxation kinetics) support the hypoth-
esis that alterations in crossbridge cycling kinetics greatly contrib-
ute to the observed weakness of NebExon55 muscle.
The studies discussed above were carried out at a maximal
activating calcium level. However, in vivo, skeletal muscle typically
is submaximally activated. Thus, submaximal parameters of muscle
function provide relevant physiological information. To test
whether submaximal force generation was affected in
NebExon55 fibres, we exposed permeabilized fibres to various cal-
cium concentrations and determined the ensuing force level. We
found that the calcium sensitivity of force generation was signifi-
cantly reduced in NebExon55 fibres, suggesting that in addition to
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maximal force generation, the capacity for submaximal force gen-
eration is greatly impaired in NebExon55 mice.
In summary, muscle of NebExon55 mice is nebulin-deficient and
produces weakness by shortening thin filament lengths, reducing
the fraction of crossbridges in the force generating state,
and reducing the force response to submaximal calcium
concentrations.
Troponin activation: a therapeutic
mechanisms to improve muscle
strength?
To date, no therapy exists that enhances force generation in pa-
tients with nemaline myopathy with nebulin mutations. Strategies
to restore thin filament length or crossbridge cycling kinetics
currently do not exist for skeletal muscle and, in part due to
the extremely large size of the nebulin gene and protein, effective
genetic strategies to combat these effects through gene
therapy are likely far off in the future. However, the lower calcium
sensitivity of force generation in patients with nemaline myopathy
with nebulin mutations (Ottenheijm et al., 2010) might offer
a more immediate therapeutic target, since a fast skeletal
muscle troponin activator has been developed that amplifies the
response of the thin filament to calcium in fast skeletal muscle
fibres (Russell et al., 2012). The fast skeletal muscle troponin
activator ‘tirasemtiv’ (formerly CK-2017357) was shown to greatly
increase the calcium-sensitivity of force generation in healthy rat
skeletal muscle fibres (Russell et al., 2012), and is currently
in phase IIa clinical studies for generalized myasthenia gravis,
and IIb clinical trials for amyotrophic lateral sclerosis (Shefner
et al., 2012).
Here we took advantage of the novel NebExon55 model to test
the ability of the fast skeletal troponin activator CK-2066260 to
improve muscle fibre strength in NebExon55 fibres. CK-2066260 is
a close structural analogue of tirasemtiv and the pharmacology of
the two compounds is the same in vitro and in vivo. Our findings
indicate that CK-2066260 greatly increases force generation in
NebExon55 fibres to levels that even exceed those observed in
untreated muscle cells from wild-type mice (Fig. 9B). Thus, fast
skeletal troponin activation might offer a therapeutic strategy for
the restoration of muscle strength in patients with nemaline
myopathy with deletion of nebulin exon 55, and possibly in pa-
tients with other nebulin mutations. Future studies should address
whether the in vivo administration of troponin activators to
nebulin knockout mouse models, such as the NebExon55 mice,
improves their survival.
In conclusion, we have generated a mouse model in which Neb
exon 55 is deleted to model a founder mutation seen frequently in
patients with nemaline myopathy. This is the first nebulin-based
model for nemaline myopathy. Our data indicate that the pheno-
type of NebExon55 mice recapitulates important features that we
observed previously in patients harbouring this particular mutation.
This severe muscle weakness, which characterizes the phenotype
of both the mouse model and patients, can be restored by a novel
compound that augments the response of the thin filament to
calcium.
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